14/02/2018 20:36:15

Veloxis Secures USD 60M in Debt Financing

Related content
13 Aug - 
Veloxis Pharmaceuticals Announces Financial Results for..
13 Jul - 
Veloxis Pharmaceuticals A/S Grants Warrants Under Exist..
04 Jun - 
Veloxis Partners with the American Society of Transplan..
Related debate
17 Aug - 
Jeg tror ikke på væsentlige milestones i 2018, da jeg f..
17 Aug - 
Ja tror dog jeg har lagt for høj vækst ind i q3 og q4.
17 Aug - 
45 mio $ er nok et meget god bud for uden milepælsbetal..

Company Release no. 01/2018

   

To: NASDAQ Copenhagen A/S                                                       14 February 2018

 

Veloxis Secures USD 60M in Debt Financing

 

Cary, NC, February 14, 2018 -- Veloxis Pharmaceuticals A/S (OMX:VELO), a specialty pharmaceutical company committed to improving the lives of transplant patients, today announced that it has obtained USD 60 million of capital from funds managed by Athyrium Capital Management, LP (“Athyrium”), a leading healthcare-focused investment firm. The proceeds from the commitment will be used to refinance Veloxis’s outstanding debt, accelerate the growth of Envarsus XR in the U.S. and help fund working capital of Veloxis Pharmaceuticals, Inc.

“We are pleased to have this opportunity to collaborate with Athyrium, a partner known for its strategic investments in healthcare. The USD 60 million non-dilutive financing enhances our cash position and provides the Company with the capital needed to execute on our commercial strategy with Envarsus. Athyrium is also committed to being a long-term partner for the Company to help fund future business development opportunities which we believe will maximize long term shareholder value,” said Craig Collard, President and Chief Executive Officer of Veloxis. 

Richard Pines, Partner at Athyrium, stated: “We are excited about funding the commercial launch of Envarsus XR. Its strong traction in a genericized market is an indication of the strength of its clinical profile, as transplant surgeons and nephrologists seek to best manage transplant rejection and immunosuppression in this fragile patient population. In addition to our interest in Envarsus XR, we are very impressed with the Veloxis management team and look forward to partnering with them as they seek to grow through business development initiatives.”

 

Transaction Terms

This financing is in the form of a five-year, floating rate, interest only note. The initial principal balance doubles the amount of debt at substantially the same cost of capital versus the previous debt instrument. The funds are structured with USD 60 million available immediately upon closing of the transaction to Veloxis Pharmaceuticals, Inc., and guaranteed by Veloxis Pharmaceuticals A/S.

 

For more information, please contact:

Craig A. Collard

President & CEO          

Phone: +1 919 591 3090         

Email: cac@veloxis.com

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a biopharmaceutical company focused on improving patient lives by identifying, developing, and commercializing meaningful products in transplantation and adjacent therapies. Utilizing our proprietary drug delivery technology (MeltDose®), Veloxis has developed and obtained FDA and EMA approval for our product, Envarsus XR (tacrolimus extended-release tablets), to aid in the prophylaxis of organ rejection in transplant recipients.  Our strategy is to continue to commercialize Envarsus XR in the U.S. with a direct salesforce and to license rights to Envarsus to proven commercial partners in other territories around the world.  In addition to expanding use of Envarsus, Veloxis is actively seeking business development and licensing targets within the areas of transplantation and adjacent specialties, and therapeutics for rare or severe disease for which chronic therapy is initiated in the large hospital setting.  Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

 

About Athyrium Capital Management

Athyrium Capital Management, LP, is a specialized asset management company that invests in the global healthcare sector. As of December 31, 2017, Athyrium had approximately $3.5 billion of assets under management. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals, including biopharma, medical devices and products, and healthcare focused services. The Athyrium team partners with management teams to implement creative financing solutions to companies’ capital needs. For more information, please visit www.athyrium.com.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Aug
VELO
Vi har diskuteret markedet for immunosuppressive medikamenter før, og jeg har i et tidligere indlæg ..
23
15 Aug
VELO
Bare t.o. Jeg taler efter planen med Craig Collard i eftermiddag og sender en artikel ud i morgen.  ..
18
13 Aug
VELO
Husk at markedet er gigantisk! Astellas' to produkter AstagrafXL og Prograf solgte for ca. 12 mia. k..
18
17 Aug
VELO
Q2-18 er udkommet og jeg har fået set lidt på regnskabet. Overordnet set fulgte selskabets resultat ..
17
13 Aug
VELO
Dette er på alle måder et super regnskab. jeg er helt enig med dem der forventer endnu en opjusterin..
16
14 Aug
VELO
Svar fra Kevin Grønnemann, Medwatch.....   Mange tak for din mail og for jeres forslag.   Det er nog..
14
16 Aug
VELO
Hej jp335671   Dine indlæg bliver næsten konsekvent filtreret væk. Er du tilknyttet MedWatch på en m..
12
13 Aug
VELO
Dejligt at der sker opjustering. Som aktionær på tredje år, har det været lidt af en ørkenvandring..
12
16 Aug
VELO
Veloxis arbejder på at blive førstevalg på de ca. 200 amerikanske sygehuse, der foretager nyretransp..
10
15 Aug
VELO
IDTrader - Skribenter som har Veloxis aktier har samlet spørgsmål ind som er sendt til medie - her e..
10

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Lifeway Foods, Inc. Announces Results for the Second Quarter Ended June 30, 2018
2
Grant of subscription rights
3
Insurance Reps Sold School Head Susie Osborne "Useless" Lloyd’s of London Policy Despite Better Options, Lawsuit Claims
4
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Zoe’s Kitchen, Inc. (ZOES) on Behalf of Stockholders and Encourages Investors to Contact the Firm
5
Hilltop Cybersecurity Announces a New CISO

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 August 2018 07:13:57
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180816.1 - EUROWEB4 - 2018-08-18 08:13:57 - 2018-08-18 07:13:57 - 1000 - Website: OKAY